Neurophysiology

Over $700 Million growth expected in EEG and EMG Devices Market during 2021-2025 | Technavio

Retrieved on: 
Monday, June 21, 2021
Branches of biology, Electrophysiology, Neurophysiology, Neurotechnology, Brain–computer interfacing, Electrodiagnosis, Electroencephalography, Ambu

The EEG and EMG devices market is expected to grow by USD 706.20 million during 2021-2025, according to Technavio.

Key Points: 
  • The EEG and EMG devices market is expected to grow by USD 706.20 million during 2021-2025, according to Technavio.
  • The EEG and EMG devices market will witness a positive impact during the forecast period owing to the widespread growth of the COVID-19 pandemic.
  • Gain more insights about the global trends impacting the future of EEG and EMG devices market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR40609
    Major Five EEG and EMG Devices Market Participants:
    Ambu AS:The company offers EEG and EMG equipment under the brand names Ambu Neuroline Cup, Ambu Neuroline Monopolar electrodes, Ambu Neuroline Concentric, and Ambu Neuroline 715.
  • EEG and EMG Devices Market 2021-2025: Segmentation
    EEG and EMG devices market is segmented as below:

Dr. Randy Pardell Announced as President of the Clinical TMS Society

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Neuroscience, Medicine, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, TMS, Todd M. Hutton

POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.

Key Points: 
  • POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.
  • Dr. Pardell's appointment was confirmed at the Clinical TMS Annual Meeting currently being held in West Palm Beach, Florida.
  • The Clinical TMS Society is an international professional association dedicated to optimizing clinical practice, awareness, and accessibility of Transcranial Magnetic Stimulation therapy.
  • Dr. Pardell has served on the Board of Directors of the Clinical TMS Society and as the Vice President 2020-21.

Inscopix Unveils First Demonstration of Optical-based ‘Wearable’ for Real-Time Measurement of Brain Activity in Non-Human Primates

Retrieved on: 
Tuesday, June 15, 2021
Mental health, Medical devices, Health, Research, Science, Biotechnology, Branches of biology, Neuroscience, Computational neuroscience, Biology, Artificial neural networks, Neural coding, Neurophysiology, Emerging technologies, Brain–computer interface, Development of the nervous system in humans, nVista™ and nVoke™ systems, Inscopix, Inc., NVISTA™ AND NVOKE™ SYSTEMS, INSCOPIX, INC.

Researchers were able to repeatedly image activity from the same neurons during sessions spanning multiple months allowing for longitudinal tracking of neural ensemble dynamics and their relationship to specific behaviors.

Key Points: 
  • Researchers were able to repeatedly image activity from the same neurons during sessions spanning multiple months allowing for longitudinal tracking of neural ensemble dynamics and their relationship to specific behaviors.
  • Neural activity selective for different directions of arm movements was observed and could be used to decode the animals reach behavior on individual trials with over 85% accuracy.
  • Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits.
  • Inscopixs partner and customer discoveries help decode the brain, inform deeper understanding of mechanisms of action and enable the screening of drugs based on efficacy.

Greenbrook TMS Announces Results of Voting at Annual and Special Meeting of Shareholders

Retrieved on: 
Monday, June 14, 2021
Biotechnology, General Health, Mental health, Medical devices, Health, Branches of biology, Articles, Neuroscience, Corporate law, Shareholders, Neurophysiology, Neuropsychology, Treatment of depression, Board of directors, Proxy, TMS, Transcranial magnetic stimulation

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the Meeting).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the Meeting).
  • Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual and Special Meeting of Shareholders and Management Information Circular of Greenbrook dated May 7, 2021 (the Circular).
  • The total number of common shares represented by holders by proxy at the Meeting was 8,276,984, representing approximately 60.26% of Greenbrooks outstanding common shares entitled to be voted.
  • All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed.

Alexander Skarsgård Reads “The Lighthouse” for Sleep Cycle

Retrieved on: 
Thursday, June 10, 2021
Entertainment, Technology, Celebrity, Mobile, Wireless, Mobile Entertainment, Audio, Video, Branches of biology, Mind, Self, Sleep, Neurophysiology

Sleep Cycle , the worlds most popular sleep tracking application, today announced the launch of The Lighthouse, a soothing sleep aid story narrated by Emmy and Golden Globe winning actor Alexander Skarsgrd.

Key Points: 
  • Sleep Cycle , the worlds most popular sleep tracking application, today announced the launch of The Lighthouse, a soothing sleep aid story narrated by Emmy and Golden Globe winning actor Alexander Skarsgrd.
  • To learn more about Sleep Cycles Sleep Aid library and listen to The Lighthouse written by Andreas Roman and narrated by Alexander Skarsgrd, click here .
  • Sleep Cycle's mission is to improve global health by empowering people to sleep better, and since the launch in 2009 Sleep Cycle has helped millions of people understand their sleep habits and improve their sleep.
  • Sleep Cycle is one of the worlds most comprehensive sources of sleep data, contributing to sleep research and coverage of sleep all over the world.

PainQx Awarded $1.5M Phase II SBIR Contract from the Defense Health Agency SBIR Program to Refine Objective Pain Assessment Technology

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Pain, Medicine, Nociception, Pain management, Electrophysiology, Neurophysiology, Electroencephalography, Small Business Innovation Research, Chronic pain, Algos

The DHA SBIR contract will enable PainQx to refine and expand the capabilities of its novel pain assessment technology, the ALGOS System.

Key Points: 
  • The DHA SBIR contract will enable PainQx to refine and expand the capabilities of its novel pain assessment technology, the ALGOS System.
  • The PainQx ALGOS System is an AI-enabled software platform that uses electroencephalogram (EEG) derived neural activity to objectively assess pain.
  • The data is processed through a series of proprietary algorithms to generate a scaled chronic pain biomarker correlating to a patients pain.
  • The DHA SBIR contract will enable PainQx to build upon the success of previously awarded National Institute on Drug Abuse (NIDA) Phase I and Phase II SBIR award for the Development of a Device to Objectively Measure Pain.

Sleep Number Presents New Data from Its 360® Smart Beds at SLEEP 2021 Annual Meeting

Retrieved on: 
Wednesday, June 9, 2021
Retail, Home Goods, General Health, Health, Branches of biology, Sleep, Biology, Sleep Number, Neurophysiology, Dream, National Sleep Foundation, Sleep disorder

Today, Sleep Number Corporation (Nasdaq: SNBR), a leader in sleep health, innovation, science and research, presented data as posters from two new studies using its 360 smart bed at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies, LLC from June 10 to 13.

Key Points: 
  • Today, Sleep Number Corporation (Nasdaq: SNBR), a leader in sleep health, innovation, science and research, presented data as posters from two new studies using its 360 smart bed at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies, LLC from June 10 to 13.
  • (Graphic: Business Wire)
    The research findings from these two new studies, presented at SLEEP 2021, add to the growing body of scientific research from our Sleep Number 360 smart bed, said Annie Bloomquist, Chief Innovation Officer, Sleep Number.
  • The 360 smart bed is an innovative device that offers proven quality sleep, an accurate, longitudinal data collection platform and the ability to understand real-world sleep behaviors.
  • Our 360 smart beds deliver individualized sleep health reports and insights, including a daily SleepIQ score, and are helping to advance meaningful sleep health solutions by applying sleep science and research.

Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Neuroscience, Medicine, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, TMS, Major depressive disorder, Todd M. Hutton

MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.

Key Points: 
  • MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.
  • The CTMSS, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS), will hold its yearly meeting June 10-12 in West Palm Beach, Florida.
  • Its an honor and exciting to present new findings at the Clinical TMS Society Meeting, from theNeuroStar Outcomes Registry, the largest depression registry in the world, said Harold A. Sackeim,PhD, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University, and presenter at the Clinical TMS Society Annual Meeting.
  • Visit the Clinical TMS Societys website to learn more about the annual meeting.

BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury

Retrieved on: 
Tuesday, June 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical trials, Branches of biology, Axon, Neuron, Rho family of GTPases, PTEN, Neurophysiology, Neuroregeneration

The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with BA-434, a novel sd-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis.

Key Points: 
  • The notice covers the critical patent application (US 16/321,229) for the proprietary method of treatment of spinal cord injury with BA-434, a novel sd-rxRNA compound that targets transient, non-permanent PTEN suppression to promote axon regeneration and reduce paralysis.
  • We look forward to continued exploration of the opportunity to allow for axon regeneration to help serve this unmet need of patients with spinal cord injury.
  • BA-434 is BioAxones novel self-delivering RNA interference compound that reduces expression of PTEN, a protein that blocks axon regeneration in adult neurons.
  • Leveraging 20 years of pioneering research in axon regeneration and diseases involving Rho/ROCK signaling, BioAxone has a clinical stage drug (BA-210) and a preclinical program (BA-434) targeting axon regeneration for treatment of spinal cord injury.

Global Nerve Repair and Regeneration Devices Market to Reach $11.8 Billion by 2026

Retrieved on: 
Tuesday, June 8, 2021
Neurophysiology, Neuroregeneration

SAN FRANCISCO, June 8, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 8, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Nerve Repair and Regeneration Devices - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period.
  • This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market.
  • The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $1.8 Billion by 2026
    The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.2 Billion in the year 2021.